Integral Diagnostics (IDX.AX) Stock Price
Integral Diagnostics Price
Over the last 14 years Integral Diagnostics grew revenue by 48.9% annually, reaching 788.62 M AUD. Earnings per share have grown at 15.9% per year over the last 13 years. For Integral Diagnostics, the net margin of 2.8% is down versus 4.1% a few years ago. At today's price the dividend yield works out to roughly 5.14%. The payout ratio is around 330% of earnings. The dividend has grown at 5.0% per year over the past 10 years. The consensus 12-month price target for Integral Diagnostics is 3.37 AUD, about 91.8% above where the stock trades today. Of 16 analysts, 14 rate the stock a buy — an overall Buy consensus.
Integral Diagnostics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Integral Diagnostics business model & stock analysis
Frequently asked questions about Integral Diagnostics
The business model of Integral Diagnostics Ltd is focused on providing comprehensive diagnostic imaging services to the medical industry. They operate a network of medical imaging clinics across Australia, offering a wide range of imaging services such as MRI, CT, ultrasound, and X-ray scans. Integral Diagnostics aims to deliver high-quality radiology services, ensuring accurate and timely diagnosis for patients. Through their state-of-the-art facilities and experienced medical professionals, they aim to consistently meet the growing demand for advanced imaging services. Integral Diagnostics Ltd aims to enhance patient care and support healthcare providers in delivering effective treatment plans.
Integral Diagnostics Ltd is primarily active in the healthcare industry. With a focus on precision radiology, the company provides a broad range of diagnostic imaging services including X-rays, ultrasounds, CT scans, and more. Integral Diagnostics operates in various sectors within healthcare, including hospitals, medical centers, and specialty clinics. With their high-quality imaging equipment and expert radiologists, Integral Diagnostics plays a crucial role in assisting healthcare professionals in accurate and timely diagnoses. As a leading player in the healthcare industry, Integral Diagnostics Ltd continues to contribute to the advancement of medical imaging and patient care.
The main competitors of Integral Diagnostics Ltd in the market include companies like Sonic Healthcare Ltd, Healius Ltd, and Capitol Health Ltd.
Integral Diagnostics Ltd is a leading medical imaging and radiology service provider in Australia and New Zealand. Established in 2008, the company has quickly grown to become a trusted name in the healthcare industry. With a strong focus on delivering high-quality diagnostic services, Integral Diagnostics utilizes advanced imaging technologies to assist in the accurate detection and diagnosis of various medical conditions. The company prides itself on its team of expert radiologists and state-of-the-art facilities, ensuring patients receive the best possible care. Integral Diagnostics continues to expand its network of clinics, striving to make diagnostic services more accessible to patients across the region.
Integral Diagnostics Ltd has achieved several significant milestones since its establishment. The company has successfully expanded its services and reach, becoming one of the leading providers of radiology and nuclear medicine services in Australia and New Zealand. Integral Diagnostics Ltd has also demonstrated consistent growth and financial success over the years. Additionally, the company has made strategic acquisitions, such as Cape Radiology and Global Diagnostics, further strengthening its position in the market. Integral Diagnostics Ltd continues to invest in advanced technology and quality patient care, striving to deliver exceptional diagnostic imaging services to its customers.
Integral Diagnostics Ltd is primarily present in Australia and New Zealand.
Integral Diagnostics Ltd represents values of excellence, innovation, and integrity. With a strong corporate philosophy emphasizing patient care and diagnostic accuracy, Integral Diagnostics aims to provide the highest quality medical imaging and radiology services. The company's commitment to advanced technology and continuous improvement ensures accurate diagnoses, timely results, and exceptional patient outcomes. By investing in cutting-edge equipment, fostering a collaborative environment, and prioritizing professional development, Integral Diagnostics maintains its status as a trusted provider in the medical imaging field. With a focus on patient-centric care, the company consistently delivers superior diagnostic services, making it a preferred choice for medical professionals and patients alike.
Analysts currently set an average price target of 3.34 AUD for the Integral Diagnostics stock (median: 3.37 AUD), implying +90.1 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the Integral Diagnostics stock: 14 recommend buying, 1 holding and 1 selling.
Converted at the current exchange rate, the Integral Diagnostics share trades at 1.09 EUR (1.75 AUD).
The Integral Diagnostics share (IDX.AX) is listed on 1 stock exchanges, including: ASX (IDX.AX).
Integral Diagnostics Ltd is a leading Australian diagnostic company that offers medical imaging and pathology services. The company was founded in 1998 and has been listed on the Australian stock exchange since 2015. Integral Diagnostics' business model is based on providing high-quality diagnostic services needed by physicians and other healthcare providers to make accurate diagnoses and ensure the best possible treatment for their patients. Integral Diagnostics operates several business divisions, including radiology services, pathology services, and clinical trials. In the radiology field, the company offers a wide range of diagnostic imaging services, including X-rays, ultrasound, MRI, and CT scans. The company has over 50 radiology practices throughout Australia and a growing presence in New Zealand. The company also offers specialized radiology services such as oncology imaging and intervention, as well as training and workshops for medical staff. Integral Diagnostics also operates a pathology division, which offers a comprehensive range of pathology services including clinical chemistry, hematology, histopathology, and microbiological testing. Integral Diagnostics' pathology services are used for diagnosing diseases and monitoring patients undergoing treatment. In the pathology division, Integral Diagnostics operates 17 laboratories throughout Australia. In addition to radiology and pathology services, Integral Diagnostics also conducts clinical trials. The company provides support to medical researchers in conducting clinical trials and evaluating the effectiveness of new treatment methods. Integral Diagnostics' clinical trials cover a wide range of medical specialties, including oncology, cardiology, and neurology. Integral Diagnostics has a robust IT system that allows for the electronic transmission of patient data and images. The company also operates an online platform through which physicians and medical professionals can access their patient data and images. This facilitates information exchange among doctors and enables quicker diagnosis and treatment of patients. Integral Diagnostics' business model is based on providing high-quality and efficient diagnostic services. The products offered by Integral Diagnostics are essential tools for physicians and medical professionals to make accurate diagnoses and ensure the best possible treatment for patients. When it comes to search engine optimization (SEO), it is important to use relevant keywords that users enter when searching for medical diagnostic services. These may include keywords such as "radiology services," "pathology services," and "clinical trials." The text should also provide the reader with a clear overview of Integral Diagnostics' business model without being too promotional.
The revenue of Integral Diagnostics is 788.62 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Integral Diagnostics is 21.93 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Integral Diagnostics is currently 30.16. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Integral Diagnostics stock.
The price-to-sales ratio (P/S) of Integral Diagnostics is currently 0.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Integral Diagnostics stock.
The Eulerpool Quality Score for Integral Diagnostics is 6/10.
The ISIN of Integral Diagnostics is AU000000IDX2. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Integral Diagnostics is IDX.AX. The ticker symbol is used to trade Integral Diagnostics shares on the stock exchange.
Integral Diagnostics stock
Integral Diagnostics Peer Group
Integral Diagnostics Ticker
Integral Diagnostics FIGI
All fundamentals and in-depth analysis of Integral Diagnostics
Our stock analysis for Integral Diagnostics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Integral Diagnostics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.